Scores by kind of claim
Each kind of claim is scored on its own, out of 100: the share that held up, with the range it likely falls in. Fewer resolved claims give a wider range.
-
Factual claims
Statements about the present or the past, checked against the record: did they hold up?
72 65 79 -
Predictions
Statements about events outside the person's control, checked once they fell due: did they come true?
66 54 78 -
Promises
Commitments to the person's or organisation's own future action, with something to deliver: was it delivered?
Insufficient record: 1 promise resolved, 5 needed for a score.
All types combined: 71 (likely 64 to 77, high confidence), from 79 claims: 60 factual claims, 19 predictions. It mixes kinds of claim in different proportions for different people, so compare people kind by kind.
Balaji Srinivasan's claims
9 claims
“And it may turn out that we need to make testing extremely routine, which would basically mainstream genomics.”
Balaji Srinivasan, podcast guest 13 March 2020 #78 Balaji Srinivasan: Exploring COVID-19 — The Knowledge Project (HappyScribe)
Testing may need to become extremely routine, effectively mainstreaming genomics.
Mixed Partly true and partly false in roughly equal measure.
The second judge would not resolve this claim; the verdict shown is the first judge's.
What would count as true or false
Judged at end-2021. The claim has two linked parts: (a) COVID testing became extremely routine, meaning frequent repeat testing built into ordinary life for large parts of the population (for example mass free home antigen tests, routine workplace or school screening, testing required for travel or venues); and (b) this mainstreamed genomics, meaning genomic or nucleic-acid sequencing and analysis became a widespread, everyday technology (for example large-scale routine viral genome sequencing for variant surveillance in many countries, and broad public familiarity with or consumer use of molecular or genomic testing). TRUE: both (a) and (b) are documented. MOSTLY TRUE: (a) clearly holds and genomic sequencing grew greatly and became routine in public health, but not quite in everyday consumer use. MIXED: (a) holds but there is no meaningful mainstreaming of genomics beyond specialist labs (or the reverse). MOSTLY FALSE: testing grew but stayed occasional or symptom-driven for most people, with no mainstreaming of genomics. FALSE: testing never became routine for most people and genomics did not spread beyond specialist use. The claim's hedge ('may') does not lower the bar for the outcome itself.
Evidence
- Twice weekly rapid testing to be available to everyone in England UK Government (GOV.UK, Department of Health and Social Care) · 5 April 2021
“Everyone in England, including those without symptoms, will be able to take a free rapid coronavirus (COVID-19) test twice a week”
- COVID-19: general public testing behaviours UK Health Security Agency (GOV.UK) · 19 October 2023
“At the end of March 2022 (the period just before the end of UTO), the percentage of people who had taken an LFD test in the last 2 weeks dropped to 40% (6) from the peak of 59% in January 2022.”
- COVID-19: general public testing behaviours UK Health Security Agency (GOV.UK) · 19 October 2023
“The UTO paved the way for widespread community based self-testing for COVID-19, allowing all individuals the means to rapidly assess their likelihood of being infectious without needing to use a laboratory process.”
- [PDF] Nathan D. Grubaugh, PhD - Congress.gov US Congress, House Committee on Science, Space, and Technology (written testimony of Yale School of Public Health epidemiologist Nathan D. Grubaugh) · 12 May 2021
“The United States has so far sequenced 0.5-1% of the total COVID-19 cases, though sequencing has significantly increased in recent months.”
Reasoning
E1 shows that from April 2021 everyone in England, including people without symptoms, could take a free rapid test twice a week. E3 describes this as widespread community self-testing. Together they support part (a), routine frequent testing, at least in England. E2's figure of 59% testing within two weeks is from January 2022, just after the end-2021 judging date. For part (b), the only evidence is E4: in May 2021 the US had sequenced 0.5–1% of COVID-19 cases, though sequencing was growing. The rapid tests in E1 and E3 are not genomic tests, and nothing here shows genomics becoming an everyday technology outside specialist labs. That matches the 'mixed' outcome in the criteria.
Cite this claim
Balaji Srinivasan, “Testing may need to become extremely routine, effectively mainstreaming genomics.” (said 13 March 2020). Verdict: mixed. Reliability API, claim c_109a8b464572, method 0.1.0+c876030c. https://epistacklabs.com/claims/c_109a8b464572
Claims without a verdict
- Unresolvable 148
- Not yet due 21
- Own records only 2
- Not researched 227
- Not checkable 1,091
Is a verdict here wrong, or do you speak for Balaji Srinivasan? Reply on the claim's own page, with the form at its foot (how replies work). Verdicts are made automatically; how verdicts and scores are made.